Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Allergy · 2023
DOI: 10.1111/all.15711 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Allergy, 2023. Verfasst von Paul E Pfeffer und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Barts Health NHS Trust, London, UK. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca, Optimum Patient Care Global.
Abstract (Originalsprache)
Background
Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti‐IgE and anti‐IL5/5R and to compare the effectiveness of both classes of treatment in real life.
Methods
This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti‐IgE and anti‐IL5/5R. The effectiveness of anti‐IgE and anti‐IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long‐term‐oral corticosteroid (LTOCS) use, asthma‐related emergency room (ER) attendance, and hospital admissions.
Results
In the matched analysis ( n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti‐IL5/5R group and 38.7% in the anti‐IgE group. Patients treated with anti‐IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti‐IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti‐IL5/5R experienced fewer asthma‐related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43).
Conclusions
In real life, both anti‐IgE and anti‐IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti‐IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Barts Health NHS Trust, London, UK.
- Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Observational and Pragmatic Research Institute, Singapore, Singapore.
- Optimum Patient Care Global, Cambridge, UK.
- Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.
- AstraZeneca, Gaithersburg, Maryland, USA.
ORCID-Profile: Nikolaos G Papadopoulos, Enrico Heffler, Désirée Larenas-Linnemann, Luis Perez-de-Llano, Eileen Wang, Celine Goh, Unnur Bjornsdottir, Arnaud Bourdin, Borja G Cosio, Liam G Heaney, Mark Hew, David J Jackson, Hsin-Kuo Bruce Ko, Cláudia Chaves Loureiro, Andriana I Papaioannou
Förderung
- AstraZeneca
- Optimum Patient Care Global
Zitieren
APA
Pfeffer, P. E., Ali, N., Murray, R., Ulrik, C., Tran, T. N., Maspero, J., Peters, M., Christoff, G. C., Sadatsafavi, M., Torres-Duque, C. A., Altraja, A., Lehtimäki, L., Papadopoulos, N. G., Salvi, S., Costello, R. W., Cushen, B., Heffler, E., Iwanaga, T., Al-Ahmad, M., …, & Papaioannou, A. I. (2023). Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both. Allergy. https://doi.org/10.1111/all.15711
Vancouver
Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, et al. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023. doi:10.1111/all.15711
BibTeX
@article{Pfeffer2023,
author = {Pfeffer, Paul E and Ali, Nasloon and Murray, Ruth and Ulrik, Charlotte and Tran, Trung N and Maspero, Jorge and Peters, Matthew and Christoff, George C and Sadatsafavi, Mohsen and Torres-Duque, Carlos A and Altraja, Alan and Lehtimäki, Lauri and Papadopoulos, Nikolaos G and Salvi, Sundeep and Costello, Richard W and Cushen, Breda and Heffler, Enrico and Iwanaga, Takashi and Al-Ahmad, Mona and Larenas-Linnemann, Désirée and Kuna, Piotr and Fonseca, João A and Al-Lehebi, Riyad and Rhee, Chin Kook and Perez-de-Llano, Luis and Perng Steve, Diahn-Warng and Mahboub, Bassam and Wang, Eileen and Goh, Celine and Lyu, Juntao and Newell, Anthony and Alacqua, Marianna and Belevskiy, Andrey S and Bhutani, Mohit and Bjermer, Leif and Bjornsdottir, Unnur and Bourdin, Arnaud and Bulow, Anna von and Busby, John and Canonica, Giorgio Walter and Cosio, Borja G and Dorscheid, Delbert R and Muñoz-Esquerre, Mariana and FitzGerald, J Mark and Gil, Esther Garcia and Gibson, Peter G and Heaney, Liam G and Hew, Mark and Hilberg, Ole and Hoyte, Flavia and Jackson, David J and Koh, Mariko Siyue and Ko, Hsin-Kuo Bruce and Lee, Jae Ha and Lehmann, Sverre and Chaves Loureiro, Cláudia and Lúðvíksdóttir, Dóra and Menzies-Gow, Andrew N and Mitchell, Patrick and Papaioannou, Andriana I},
title = {Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both},
journal = {Allergy},
year = {2023},
doi = {10.1111/all.15711}
}
EUVIMED